RxDoctor Payments Data

Shobha Sekhon, MD

Family Medicine · Madera, CANPI 1710089784

Payments from drug & device makers

$4,794in general payments, 2019–2025

Across 215 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$614
  • Sanofi-aventis U.S. LLC$421
  • Amarin Pharma, Inc.$344
  • Novo Nordisk$328
  • AbbVie$298
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,782100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,794 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$152,285
Medicare patients
268
Services billed
1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$100,917
EnbrelEtanercept13$97,092
JanuviaSitagliptin Phosphate64$86,020
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$64,749
JardianceEmpagliflozin55$62,164
FarxigaDapagliflozin Propanediol44$54,523
EliquisApixaban36$31,556
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$30,504
TrulicityDulaglutide13$19,195
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$17,495
XareltoRivaroxaban18$11,364
Levothyroxine Sodium538$8,035
VascepaIcosapent Ethyl15$7,094
Humalog Kwikpen U-100Insulin Lispro29$6,959
Tresiba Flextouch U-100Insulin Degludec13$6,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$328$100,91769 claims
AmgenEnbrel$151$97,09213 claims
MerckJanuvia$100$86,02064 claims
GSKTrelegy Ellipta$252$64,74958 claims
Boehringer IngelheimJardiance$129$62,16455 claims
AstraZenecaFarxiga, Symbicort$1,053$60,75556 claims
PfizerEliquis$194$31,55636 claims
Lilly USA, LLCTrulicity$614$19,19513 claims
Johnson & JohnsonXarelto$122$11,36418 claims
AbbVieSynthroid$298$2,49238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Madera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →